Origen, presente y futuro de las resistencias en tuberculosis

Archivos de Bronconeumologia

Volumn 37, Issue 1, 2001, Pages 35-42

  Caminero Luna, J A ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FORECASTING; HUMAN; LUNG TUBERCULOSIS; MICROBIOLOGY; REVIEW; TUBERCULOSIS;

FORECASTING; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 0035220805     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2896(01)75005-3     Document Type: Article

References (101)

1. Kapur V, Whittam TS, Musser JM. Is Mycobacteriuin tuberculosis 15000 years old? J Infect Dis 1994; 170: 1348-1349.
2. Hayman J. Mycobacterium ulcerans: an infection from Jurasic time? Lancet 1984; 2: 1015-1016.
3. Daniel TM. The origins and precolonial epidemiology of tuberculosis in the Americas: can we figure them out? Int J Tuberc Lung Dis 2000; 4: 395-400.
4. Stead WW, Eisenah KD, Cave MD, Beggs ML, Templeton GL, Thoen CO et al. When did Mycobacteriuin tuberculosis infection first occur in the new world? An important question with public health implications. Am J Respir Crit Care Med 1995; 151: 1267-1268.
5. Hare R. The antiquity of diseases caused by bacteria and viruses. A review of the problem from a bacteriologist's point of view. En: Brothwell D, Sandison AT, editores. Diseases in antiquity. A survey of the diseases, injuries and surgery of early populations. Springfield: Charles C Thomas, 1967; 115-131.
6. Bates JH, Stead WW. The history of tuberculosis as a global epidemic. Med Clin North Am 1993; 77: 1205-1217.
7. Haas F, Haas SS. The origins of Mycobacterium tuberculosis and the notion of its contagiousness. En: Rom WN, Garay SM, editores. Tuberculosis. Boston: Little, Brown and Company, 1996; 3-19.
8. World Health Organization. Global tuberculosis control. WHO Report 1999. Ginebra: World Health Organization, 1999.
9. World Health Organization. Anti-tuberculosis drug resistance in the world: The WHO / IUATLD global project on anti-tuberculosis drug resistance surveillance 1994-1997. WHO/TB/97.229. Ginebra: World Health Organization, 1997.
10. Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F et al. Global surveillance for anti-tuberculosis drug resistance, 1994-1997. N Engl J Med 1998; 338: 1641-1649.
11. World Health Organization. WHO report on the tuberculosis epidemic. WHO/TB/97.224. Ginebra: World Health Organization, 1997.
12. Caminero JA. Resistencia primaria a fármacos antituberculosos. Med Clin (Barc) 1989; 93: 30-36.
13. Committee on Treatment of International Union Against Tuberculosis (IUAT). Probability of drug resistant. Documents prepared by the Committee on Treatment of IUAT. París, 1975.
14. Shimao T. Drug resistance in tuberculosis control. Tubercle 1987; 68 (Supl): 5-15.
15. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995; 8: 496-514.
16. Riska PF, Jacobs WR Jr, Alland D. Molecular determinants of drug resistance in tuberculosis. Int J Tuberc Lung Dis 2000; 4: S4-S10.
17. Yew WW, Chau CH. Drug resistant tuberculosis in the 1990s. Eur Respir J 1995; 8: 1184-1192.
18. Mitchison DA. Drug resistance in mycobacteria. Br Med J 1984; 40: 84-90.
19. Ausina V. Tuberculosis multirresistente. Puntualizaciones y reflexiones sobre un tema polémico y de candente actualidad. Med Clin (Barc) 1996; 106: 15-18.
20. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Unit, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: S231-S279.
21. Cowley R, Briney R. Primary drug resistant tuberculosis in Vietnam veterans. Am Rev Respir Dis 1970; 101: 703.
22. Kim SJ, Kim SC, Bai GH. Drug resistance Mycobacterium tuberculosis isolated from patients with pulmonary tuberculosis discovered in the fourth nation-wide tuberculosis prevalence survey in 1980 in Korea. Tuberc Respir Dis (Korean) 1982; 29: 1-10.
23. Mitchison DA, Nunn AJ. Influence of initial drug resistance as the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
24. Rouse DA, Morris SL. Molecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mycobacterium bovis. Infect Immunol 1995; 63: 1427-1433.
25. Ad Hoc Committee on the Scientific Assembly on Microbiology, Tuberculosis, and Pulmonary Infections. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359-1374.
26. International Union Against Tuberculosis and Lung Diseases. Committee of Treatment. BuI Int Union Tuberc Lung Dis 1988; 63: 64-72.
27. Becerra MC, Bayona J, Freeman J, Farmer PE, Kim JY. Redefining MDR-TB transmission 'hot spot'. Int J Tuberc Lung Dis 2000; 4: 387-394.
28. March P. La transmision de la resistencia al Mycobacterium tuberculosis en los infectados por el VIH. La Ilamada tercera epidemia del VIH. Med Clin (Bare) 1994; 102: 98-100.
29. Canetti G, Kreis B, Thibier R, Gay PH, Le Lirzin M. Données actuelles sur la résistance primaire dans la tuberculose pulmonaire de l'adulte in France. Deuxième enquète. Rev Tuberc Pneumol 1967; 31: 433-474.
30. March P. Resistencias primarias y secundarias a las drogas antituberculosas. Revista IBYS 1970; 28: 137-174.
31. Davies PDO. Tuberculosis in the United States. Am Rev Respir Dis 1993; 147: 497.
32. Caminero JA. Situación actual de La tuberculosis en España. Arch Bronconeumol 1994; 30: 371-374.
33. March P, López-Sanmartín JL, Smidt G, Seix T. Epidemiological significance of primary resistance in Spain. Refutation of the concept on transmission of resistant strains of Mycobacterium tuberculosis. Chest 1977; 72: 683-684.
34. Styblo K. Epidemiology of tuberculosis. Royal Netherlands Tuberculosis Association Selected Papers. La Haya: Royal Netherlands Tuberculosis Association, 1991.
35. American Thoracic Society. Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161: 1371-1395.
36. Middlebrook G. INH resistance and catalase activity of the tubercle bacilli. Am Rev Tuberc 1954; 69: 471-472.
37. Cohn ML, Oda U, Kovitz C, Middlebrook G. Studies on isoniazid and tubercle bacilli: the isolation of isoniazid-resistant mutants in vitro. Am Rev Tuberc 1954; 70: 465-475.
38. Cohn ML, Kovitz C, Oda U, Middlebrook G. Studies on isoniazid and tubercle bacilli: the growth requirements, catalase activities, and pathogenic properties of isoniazid-resistant mutants. Am Rev Tuberc 1954; 70: 641-664.
39. th Conference on Chemotherapy of Tuberculosis, VA-Armed Forces, 1958; 264.
40. Dantzker DR, Steinberg NH, Kmiecik JE. Primary drug-resistant tuberculosis in Vietnam Veterans 1967 to 1970. Am Rev Respir Dis 1972; 106: 273-274.
41. Etzkorn ET, Lillis PK, McAllister CK. Tuberculosis in Korea. The relationship between prior therapy and drug resistance. Chest 1986; 90: 247-250.
42. Steiner P, Rao M, Victoria MS, Hunt J, Steiner M. A continuing study of primary drug-resistant tuberculosis among children observed at the Kings County Hospital Medical Center between the years 1961 and 1980. Am Rev Respir Dis 1983; 128: 425-428.
43. Snider DE, Kelly GD, Thompson NJ, Kilbum JD, Good RC. Infectiousness and pathogenicity of drug resistant Mycobacterium tuberculosis. Am Rev Respir Dis 1981; 123 (Supl 2): 254-255.
44. Adler GA, Lynne-Davies P, Truant JP, Muller BF. Primary drug resistant in tuberculosis. Am Rev Respir Dis 1981; 123 (Supl 2): 256-258.
45. Pitchenik AE, Burr J, Laufer M, Miller G, Cacciatore R, Bigler WJ et al. Outbreaks of drug-resistant tuberculosis at AIDS centre. Lancet 1990; 336: 400-401.
46. Centers for Disease Control. Nosocomial transmission of multidrug-resistant tuberculosis to health care workers and HIV-infected patients in an urban hospital - Florida. MMWR 1990; 39: 718-772.
47. Center for Disease Control. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons - Florida and New York, 1988-1991. MMWR 1991; 40: 585-591.
48. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Dordillo EM et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326: 1514-1521.
49. Snider DE, Roper WL. The new tuberculosis. N Engl J Med 1992; 326: 703-705.
50. Gordin K. Tuberculosis control. Back to the future? JAMA 1992; 267: 2649-2650.
51. Dooley SW, Jarvis WR, Martone WJ, Snider DE. Multidrug-resistant tuberculosis. Ann Intern Med 1992; 117: 257-259.
52. Glassroth J. Tuberculosis in the United States. Looking for a silver lining among the clouds. Am Rev Respir Dis 1992; 146: 278-279.
53. Rieder HL. Misbehaviour of a dying epidemic: a call for less speculation and better surveillance. Tuberc Lung Dis 1992; 73: 181-183.
54. Watson JM. Tuberculosis in Britain today. Notifications are no longer falling. Br Med J 1993; 306: 221-222.
55. Israel HL. Chemoprophylaxis for tuberculosis. Respir Med 1993; 87: 81-83.
56. Bromberg A, Bromberg R, Bonk S, Tick L, Hanna B, Rom WN. The third epidemic: drug resistant tuberculosis. Am Rev Respir Dis 1992; 145 (Supl 2): A185.
57. Centers for Disease Control. National action plan to combat multidrug-resistant tuberculosis. MMWR 1992; 41: 5-8.
58. Center of Disease Control. Meeting the challenge of multidrug-resistant tuberculosis: summary of a conference. MMWR 1992; 41: 51-57.
59. Fischt MA, Daikos GL, Uttamchandani RB, Poblete RB, Moreno JN, Reyes RR et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992; 117: 177-183.
60. Beck-Sagué C, Dooley SW, Hutton MD, Otten J, Breeden A, Crawford JT et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA 1992; 268: 1280-1286.
61. Pearson ML, Jereb JA, Frieden TR, Crawford JT, Davis BJ, Dooley SW et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers. Ann Intern Med 1992; 117: 191-196.
62. Center for Disease Control. Management of persons exposed to multidrug-resistant tuberculosis. MMWR 1992; 41: 61-71.
63. Menzies D, Fanning A, Yuan L, Fitzgerald M. Tuberculosis among health care workers. N Engl J Med 1995; 332: 92-98.
64. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328: 1137-1144.
65. Clancy L. Transmisibilidad de la tuberculosis. Bol Union Int Tuberc Enf Respir 1990; 65: 77-78.
66. Riley RL, Mills CC, O'Grady F, Sultan LU, Wittsadt F, Shivpuri DN. Infectiousness of air tuberculosis ward. Am Rev Respir Dis 1962; 85: 511-525.
67. Snider DE Jr, Kelly GD, Cauthen GM, Thompson NJ, Kilbum JO. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985; 132: 125-132.
68. Edwards D, Kirkpatrick CH. The immunology of mycobacterial diseases. Am Rev Respir Dis 1986; 134: 1062-1071.
69. Dannenberg AM. Immune mechanisms in the pathogenesis of pulmonary tuberculosis. Rev Infect Dis 1989; 11: S369-S378.
70. Telenti A, Imboden P, Marchesi F, Schmidheini T, Bodmer T. Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob Agents Chemother 1993; 37: 2054-2058.
71. Ohno H, Koga H, Kuroita T, Tomono K, Ogawa K, Yanagihara K et al. Rapid prediction of rifampin susceptibility of Mycobacterium tuberculosis. Am J Respir Crit Care Med 1997; 155: 2057-2063.
72. Morris S, Bai G, Suffys P, Portillo-Gomez L, Fairchok M, Rouse D. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis 1995; 171: 954-960.
73. Williams DL, Waguespack C, Eisenach K, Crawford JT, Portaels F, Salfinger M et al. Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother 1994; 38: 2380-2386.
74. Kapur V, Li L, Iordanescu S, Hamrick MR, Wanger A, Kreiswirth BN et al. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 1994; 32: 1095-1098.
75. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358: 591-593.
76. Kelley CL, Rouse DA, Morris SL. Analysis of aphC gene mutations in isoniazid-resitant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 2057-2058.
77. Sreevatsan S, Pan X, Zhang Y, Deretic V, Musser JM. Analysis of the oxyR-ahpC region isoniazid resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Antimicrob Agents Chemother 1997; 41: 600-606.
78. Mdluli K, Slayden RA, Zhu Y, Ramaswamy S, Pan X, Mead D et al. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science 1998; 280: 1607-1610.
79. Telenti A, Honore N, Bernasconi C, March J, Ortega A, Heym B et al. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol 1997; 35: 719-723.
80. Caminero JA. Transmisibilidad y patogenia de la tuberculosis multirresistente. XIV Congreso Centroamericano y del Caribe de Neumología. Managua, Nicaragua, 15 de marzo de 2000.
81. Ministerio de Sanidad y Consumo. Grupo de trabajo sobre tuberculosis. Consenso nacional para el control de la tuberculosis en España. Med Clin (BarC) 1992; 98: 24-31.
82. American Thoracic Society. Centers for Disease Control. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359-1374.
83. a ed.). Unión Internacional contra la Tuberculosis y Enfermedades Respiratorias. París, 1996.
84. a ed.). Ginebra, 1997.
85. Valenzuela MT, García P, Ponce J, Lepe R, Velasco M, Piffardi S. Drug resistance of M. tuberculosis in Chile: rates of initial resistance for 1986 and acquired resistance for 1985. Bull Int Union Tuberc Lung Dis 1989; 64: 13-14.
86. Chaulet P. Tuberculose et transition épidemiologique: le cas de l'Algerie. Ann Inst Pasteur 1993; 4: 181-187.
87. Fujiwara PI, Larkin C, Frieden TR. Directly observed therapy in New York City: history, implementation, results, and challenges. Clin Chest Med 1997; 18: 135-148.
88. Marrero A, Caminero JA, Rodríguez R, Billo NE. Towards elimination of tuberculosis in a low income country: the experience of Cuba, 1962-1997. Thorax 2000; 55: 39-45.
89. Styblo K, Dankova D, Drapela J, Galliova J, Jezek Z, Krivanek J et al. Epidemiological and clinical study of tuberculosis in the district of Kolin, Czechoslovakia: report for the first 4 years of the study, 1961-64. Bull World Health Org 1967; 37: 819-874.
90. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274: 945-951.
91. Weiss SE, Slocum PC, Blais FX, King B, Nunñ M, Matney GB et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179-1184.
92. World Health Organization. Tuberculosis programme. Framework for effective tuberculosis control. Ginebra: World Health Organization, 1994, WHO/TB/94.179.
93. Caminero JA, Pavón JM, Rodríguez de Castro F, Díaz F, Julià G, Caylà JA et al. Evaluation of a directly observed six month fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance. Thorax 1996; 51: 1130-1133.
94. Anónimo. The promise and reality of fixed dose combinations with rifampin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization. Tuberc Lung Dis 1994; 75: 180-181.
95. Coombs DL, Geiter LJ, O'Brien RJ. The UHPS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990; 112: 397-406.
96. Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-months regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis 1991; 143: 707-712.
97. Moulding T, Dutt AK, Reichman LB. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med 1995; 122: 951-954.
98. Acocella G. Human bioavailability studies. Bull Int Union Tuberc Lung Dis 1989; 64: 38-40.
99. Uplekar MW, Rangan S. Private doctors and tuberculosis control in India. Tuberc Lung Dis 1993; 74: 332-337.
100. Olle-Goig JE, Cullity JE, Vargas R. A survey of prescribing patterns for tuberculosis treatment amongst doctors in a Bolivian city. Int J Tuberc Lung Dis 1999; 3: 74-78.
101. Caminero JA. Estado actual de los programas de control de la tuberculosis en Espana e Hispanoamérica. International Union Against Tuberculosis and Lung Disease World Conference on Lung Health. Madrid: 16 de septiembre de 1999.